Archer Investment Corporation’s CRISPR Therapeutics CRSP Stock Holding History

Archer Investment Corporation’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09K	Hold	20	–	–	﹤0.01%	1104
2026 Q1	$951	Hold	20	–	–	﹤0.01%	1121
2025 Q4	$1.05K	Hold	20	–	–	﹤0.01%	1050
2025 Q3	$1.3K	Hold	20	–	–	﹤0.01%	1044
2025 Q2	$973	Hold	20	–	–	﹤0.01%	1038
2025 Q1	$681	Hold	20	–	–	﹤0.01%	1028
2024 Q4	$787	Hold	20	–	–	﹤0.01%	1017
2024 Q3	$940	Sell	20 -200	-91%	-$10.1K	﹤0.01%	987
2024 Q2	$11.9K	Hold	220	–	–	﹤0.01%	633
2024 Q1	$15K	Hold	220	–	–	﹤0.01%	585
2023 Q4	$13.8K	Buy	220 +200	+1,000%	+$11.1K	﹤0.01%	597
2023 Q3	$908	Hold	20	–	–	﹤0.01%	935
2023 Q2	$1.12K	Sell	20 -135	-87%	-$7.66K	﹤0.01%	902
2023 Q1	$7.01K	Hold	155	–	–	﹤0.01%	617
2022 Q4	$6.3K	Hold	155	–	–	﹤0.01%	593
2022 Q3	$10.1K	Hold	155	–	–	﹤0.01%	527
2022 Q2	$9.42K	Hold	155	–	–	﹤0.01%	538
2022 Q1	$9.53K	Sell	155 -2,965	-95%	-$186K	﹤0.01%	548
2021 Q4	$236K	Hold	3,120	–	–	0.08%	207
2021 Q3	$349K	Hold	3,120	–	–	0.13%	170
2021 Q2	$505K	Hold	3,120	–	–	0.2%	117
2021 Q1	$380K	Buy	+3,120	New	+$471K	0.16%	148
2019 Q4	–	Sell	-7,500	Closed	-$307K	–	611
2019 Q3	$307K	Buy	+7,500	New	+$358K	0.19%	140

Other funds holding CRSP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Archer Investment Corporation's CRSP Position: Q2 2026 in Review

Archer Investment Corporation held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 20 shares worth $1.09K. The position accounts for ﹤0.01% of the portfolio, ranked #1104.

Archer Investment Corporation first reported a position in CRSP in Q3 2019 and has held it in 23 quarters since. The position peaked at $505K in Q2 2021. 349 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Archer Investment Corporation held 20 shares of CRISPR Therapeutics worth $1.09K as of Q2 2026.
Archer Investment Corporation left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Archer Investment Corporation's portfolio in Q2 2026, its #1104 holding.
Archer Investment Corporation first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 23 quarters since.
Archer Investment Corporation's CRISPR Therapeutics position peaked at $505K in Q2 2021.
349 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Archer Investment Corporation's 13F filing for Q2 2026, filed 3 Aug 2026.